Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced results from the phase 3 ENGAGE AF-TIMI 48 study.(1) This clinical trial found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban met the...
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced results from the phase 3 ENGAGE AF-TIMI 48 study.(1) This clinical trial found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban met the...
Daiichi Sankyo Company, Limited...